Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Cardiol Young ; 32(7): 1077-1084, 2022 Jul.
Article in English | MEDLINE | ID: mdl-34551832

ABSTRACT

BACKGROUND: Prognosis of fetuses with hydrops and tachyarrhythmia has been portrayed as poor in most published reports. This might lead to biased counselling, unnecessary caesarean section, preterm delivery, and even termination of pregnancy. AIMS: To evaluate contemporary fetal and postnatal outcomes of hydropic fetuses with fetal tachyarrhythmia when it is treated effectively and monitored systematically. METHODS: This is a retrospective review of a single centre experience at the University Hospital of Wales over a 20-year period. All fetuses received high doses of flecainide and digoxin combination treatment. Tachycardia response rate, time to arrhythmia and hydrops resolution, fetal and postnatal morbidity, and mortality rates were analysed. RESULTS: Twenty fetuses were diagnosed with hydrops fetalis and received treatment. The mechanism of fetal tachyarrhythmia was supraventricular tachycardia in thirteen and atrial flutter in eight cases. Among the 20 fetuses treated, the overall tachycardia response rate was 90% (18/20) with the restoration of sinus rhythm in 85% (17/20) of the cases. The median time to restore sinus rhythm or to rate control of the arrhythmia was 1.5 days (range 12 hours to 13 days). Hydrops resolved in 17 of the 20 fetuses, with a median time of 12 days (range 3-21 days). Four fetuses went into spontaneous preterm birth and one fetus was delivered early due to worsening hydrops. No significant neurological morbidity was observed in surviving neonates and infants on clinical examination. There was one postnatal death due to respiratory complications of prematurity in the non-responsive supraventricular tachycardia case. CONCLUSIONS: High-dose flecainide and digoxin combination offers effective treatment strategy in fetuses with hydrops and tachyarrhythmia with favourable outcomes. This study may guide more realistic counselling for pregnancies complicated by tachyarrhythmia and hydrops.


Subject(s)
Fetal Diseases , Heart Failure , Premature Birth , Tachycardia, Supraventricular , Anti-Arrhythmia Agents/therapeutic use , Arrhythmias, Cardiac/complications , Cesarean Section , Digoxin/therapeutic use , Female , Fetal Diseases/diagnosis , Fetal Diseases/drug therapy , Flecainide/therapeutic use , Heart Failure/complications , Humans , Hydrops Fetalis , Infant, Newborn , Pregnancy , Retrospective Studies , Tachycardia/complications , Tachycardia/drug therapy , Tachycardia, Supraventricular/complications , Tachycardia, Supraventricular/diagnosis , Tachycardia, Supraventricular/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL